0 (0%)		06-29 19:26
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	31.61	1-year :	31.69
Resists	First :	27.06	Second :	27.13
Pivot price	27.02
Supports	First :	26.95	Second :	22.43
MAs	MA(5) :	27.01	MA(20) :	27.03
	MA(100) :	26.76	MA(250) :	26.31
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	24.9	D(3) :	31.6
RSI	RSI(14): 47.5
52-week	High :	27.13	Low :	25.46

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PMMR ] has closed above bottom band by 27.8%. Bollinger Bands are 22.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	27.17 - 27.43	27.43 - 27.58
Low:	26.42 - 26.77	26.77 - 26.98
Close:	26.59 - 27.16	27.16 - 27.5

Mon, 01 Jun 2026
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress

Fri, 29 May 2026
Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC - CancerNetwork

Mon, 04 May 2026
Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study - Nature

Thu, 23 Apr 2026
And just like that, Eric Adams’ last PMMR is out - City & State New York

Mon, 23 Feb 2026
DUO-E Phase III Trial: Durvalumab Plus Olaparib Maintenance in pMMR Endometrial Cancer - Oncodaily

Wed, 28 Jan 2026
PD-1–Based Neoadjuvant Therapy Benefits Select Patients With pMMR Rectal Cancer - Targeted Oncology

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.